Clinical Trial Search

Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D). — 437; 1 Participants

Primary: American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale (AOFAS) — 97.8; 98.5 units on a scale

Primary: Early Clinical Response (ECR) — 336; 334; 29; 31 Participants

Primary: Change in Cognitive Function, Assessed by Scores on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery…

Primary: Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12 — 35.8; 43.5; 11.8 percentage of participants — p=0.002

Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — 0; 7 Participants

Primary: Mean Change in Best-corrected Visual Acuity (BCVA) From Baseline to 24 Months. — 3.2; 2.5 Letters — p=0.787

Primary: Change From Baseline at Day 168 in Mean Daytime Physical Activity — -108266; -98373 day-counts — p=0.091

Primary: Changes in Motor-evoked Potentials Ratios — 1.32; 0.73; 1.03 Ratio (unit: uV)

Primary: Number of Participants Free of Adverse Effects at 6 Months Post Procedure — 15 Participants

Primary: Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale — 1.82; 1.71; 0.58; 1.40 units on a scale

Primary: Number of Thoracic Spinal Segments Successfully Visualized With TEE — 12; 10 Thoracic segments

Primary: Cue-elicited Craving — 2.1; 2.2 units on a scale

Primary: Early Clinical Response (ECR) — 241; 248; 29; 21 Participants

Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…